Study suggests current drug shortages in US will be worsened by COVID-19 pandemic
A newly released paper has revealed that the shortages of medications in the US at present will be increased further due to the COVID-19 outbreak.
List view / Grid view
A newly released paper has revealed that the shortages of medications in the US at present will be increased further due to the COVID-19 outbreak.
Following a record level of data collated by WHO, the organisation has emphasised that new antibiotics need to be developed to tackle the rise of global antimicrobial resistance.
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
Coating the tetanus portion of the DTP vaccine in silica rendered it thermally stable up to 100°C and able to be distributed without refrigeration.
The RECOVERY trial has stopped enrolment for the hydroxychloroquine arm after data revealed the drug had no meaningful benefit for hospitalised COVID-19 patients.
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
The vaccine alliance said the Covax AMC programme is the first in a series of financing programmes to ensure low- and middle-income countries will have access to COVID-19 vaccines.
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
Global pharma regulators met to discuss measures to ensure supply continuity, flexible regulatory policies and their expectations for COVID-19 clinical trials.
Scientists reveal 76 percent of critically ill trial participants treated with convalescent plasma are recovering, with almost half now discharged from hospital.
The company announces it has been task ordered by BARDA to assist in the US government’s efforts to deliver COVID-19 vaccines.
Researchers have identified 27 biomarkers that could be used to predict the course of SARS-CoV-2 infection and whether a patient with COVID-19 will become severely ill.
The Russian Direct Investment Fund (RDIF) and the ChemRar Group are to deliver the doses of avifavir, approved in Russia as a COVID-19 therapeutic, to Russian hospitals.
Advent announced it has manufactured and delivered the first 4,000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.